CLINICAL TRIALS PROFILE FOR LUPKYNIS
✉ Email this page to a colleague
All Clinical Trials for LUPKYNIS
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05306873 ↗ | Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2022-04-18 | The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients. Treatment effects will be evaluated within the individual immunologically-homogenous subsets defined at screening. This study will also explore and compare pre-randomization gene expression patterns among responders and non-responders to MMF and MMF plus voclosporin, use comprehensive immunophenotyping to study the immunologic changes that accompany treatment- induced disease improvement and to better understand immunologic changes associated with the loss of clinical response. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LUPKYNIS
Condition Name
Clinical Trial Locations for LUPKYNIS
Trials by Country
Clinical Trial Progress for LUPKYNIS
Clinical Trial Phase
Clinical Trial Sponsors for LUPKYNIS
Sponsor Name